Co-Diagnostics

Co-Diagnostics Inventory

The Inventory of Co-Diagnostics (CODX) as of Nov 20, 2026 is 992,397.00 USD. In the previous year, Inventory was 1.07 M USD — a change of -7.49% (lower).

Inventory

992,397.00USD

YoY

-7.49%

Last updated:

Inventory of Co-Diagnostics is 2025 992,397.00 USD. Inventory of Co-Diagnostics was 2024 1.07 M USD. It decreases by -7.49% lower compared to the previous year.

The Co-Diagnostics Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
18,153.00 USD
Jan 1, 2019
197,168.00 USD
Jan 1, 2020
8.00 M USD
Jan 1, 2021
2.00 M USD
Jan 1, 2022
5.31 M USD
Jan 1, 2023
1.66 M USD
Jan 1, 2024
1.07 M USD
Jan 1, 2025
992,397.00 USD
The Co-Diagnostics Inventory history
YEARInventoryYoY
992,397.00USD-7.49%
1.07 MUSD-35.56%
1.66 MUSD-68.65%
5.31 MUSD+164.97%
2.00 MUSD-74.93%
8.00 MUSD+3,955.01%
197,168.00USD+986.15%
18,153.00USD+100.19%
9,068.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Inventory of Co-Diagnostics is 992,397.00 USD in 2025.

Inventory of Co-Diagnostics changed from 1.07 M USD to 992,397.00 USD, representing a -7.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Co-Diagnostics

All Key Metrics — Co-Diagnostics